Optimal Therapy for Stroke Prevention in Atrial Fibrillation: Is it Left Atrial Appendage Closure?

Harold Rivner¹ and Jeffrey Goldberger¹

¹University of Miami

January 28, 2022

Optimal Therapy for Stroke Prevention in Atrial Fibrillation: Is it Left Atrial Appendage Closure?

Harold Rivner, MD¹

Jeffrey J. Goldberger, MD, MBA¹

¹ Cardiovascular Division, Department of Medicine, University of Miami Leonard M. Miller School of Medicine, Miami, FL

Corresponding author:
Jeffrey J. Goldberger, M.D.
University of Miami Miller School of Medicine
Cardiovascular Division
1120 NW 14th St.
Miami, FL 33136
Telephone: (305) 243-8092
Fax: (305) 243-1731
E-mail: j-goldberger@miami.edu

Sarris-Michopoulos et al. reviewed the role of the left atrial appendage (LAA) in atrial fibrillation (AF) related stroke and current techniques for targeting it for stroke reduction.¹ The authors propose that further trials to assess LAA exclusion as an alternative to anticoagulation for patients with AF should strongly be considered. Any such consideration should take into account the potential risks and benefits, and ultimately be supported by randomized clinical trial data. The latter is lacking at the present time, so we will consider the potential risks and benefits.

The LAA is often considered to be a vestigial portion of the left atrium; however, it does have a physiologic role in humans. The LAA is a remnant of the embryonic left atrium that develops during the third week of fetal life. It has several functions that continue into adulthood including serving as a reservoir during left ventricular systole, a conduit for blood from the pulmonary veins into the left ventricle during diastole, a chamber to augment left ventricular filling in late diastole, and a filling chamber for volume reserve. Furthermore, the LAA plays an important endocrine role. It contains stretch receptors to excrete atrial natriuretic peptide in response to changes in left atrial pressure to increase natriuresis. Removal of the LAA eliminates these functional roles. Interestingly, it has been shown that patients undergoing LAA exclusion have elevated left atrial pressure.
It has been established that patients with AF undergoing cardiac surgery for another indication benefit from LAA occlusion at the time of surgery. In the LAAOS III (Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke) multicenter trial, 4,811 participants with a mean CHADS$_2$-VASc score of 4.2 were randomized to undergo either LAA occlusion or no occlusion. The patients were followed for a mean of 3.8 years. Stroke or systemic embolism occurred in 114 participants (4.8%) in the occlusion group and 168 (7.0%) in the no-occlusion group (HR 0.67, 95% CI: 0.53-0.85, p = 0.001). Of note, 76.8% of patients remained on oral anticoagulation at 3 years, supporting the role of LAA occlusion as an adjunct to and not a replacement for anticoagulation.

The concept of LAA occlusion/ligation as an alternative to anticoagulation is considered based on the data that approximately 90% of non-rheumatic atrial fibrillation left atrial thrombi can be localized to the LAA. If correct, this implies that about 10% of left atrial thrombi in patients with atrial fibrillation would not be addressed by LAA occlusion. If anticoagulation is not contraindicated, there would therefore theoretically still be benefit for anticoagulation to address these non-LAA thrombi. Future clinical trials to assess the additional benefit for anticoagulation in patients who have undergone LAA occlusion/ligation would be important to address this question but will be challenging due to the noninferiority design that would be required and the low event rate.

Available data from trials comparing LAA closure to warfarin have provided some evidence of lower efficacy for LAA closure in reducing ischemic stroke. The most studied device, the endovascularly placed Watchman, shows a trend towards reduced efficacy in preventing ischemic stroke. The five-year outcomes of the PREVAIL (Evaluation of the WATCHMAN LAA Closure Device in Patients with Atrial Fibrillation Versus Long Term Warfarin Therapy) did not meet noninferiority for the first composite coprimary endpoint of stroke, systemic embolism, or cardiovascular/unexplained death. A meta-analysis of the PREVAIL and PROTECT AF (WATCHMAN Left Atrial Appendage system for embolic Protection in Patients with Atrial Fibrillation) trials did show a similar composite endpoint of stroke, systemic embolism, or cardiovascular death between groups (HR 0.82, 95% CI 0.58-1.17 p = 0.27). However, there was a numerically higher rate of ischemic stroke in the Watchman group (HR 1.71, 95% CI 0.94-3.11, p = 0.08) but a lower rate of hemorrhagic stroke (HR 0.20, 95% CI 0.07-0.56, p = 0.0022).

It is debatable how to apply these data in the current age of non-warfarin direct oral anticoagulant (DOAC) use. Compared to warfarin, DOACs have a lower risk of both stroke/systemic embolism (HR 0.81, 95% CI 0.74-0.89) and intracranial bleeding (HR 0.45, 95% CI 0.37-0.56). The PRAGUE-17 (Left Atrial Appendage closure versus Novel Anticoagulation Agents in Atrial Fibrillation) trial compared Watchman closure with DOACs. Closure with the Watchman device met non-inferiority for the composite endpoint of cardiovascular death, all-stroke/transient ischemic attack, clinically relevant bleeding, and device/procedure-related complications (sHR = 0.81, 0.56-1.18, p=0.27, p-value for noninferiority = 0.006). There was a numerical but not statistically significant increase in the all-stroke rate (HR 1.38, 0.63-3.03, p =0.42).

It is unclear how the data from Watchman would extend to surgical LAA occlusion. While these surgical techniques appear promising, the data presented in the review article by Sarris-Michopoulos et al. is entirely from observational studies. The total number of subjects in these studies is 442 patients. This is less than aforementioned randomized Watchman trials which enrolled 707 patients in the PROTECT AF, 407 patients in PREVAIL, and 402 patients in PRAGUE-17. Even these studies enrolled many fewer patients than the seminal trials of DOACs versus warfarin: 18,133 in RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy), 14,264 in ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor XA Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), 18,201 patients in ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation), and 21,105 patients in ENGAGE AF-TIMI 48 (The Effective Anticoagulation with a Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) for a total of 71,703 patients. It is therefore difficult to make conclusions regarding the safety and efficacy of these LAA occlusion techniques. Furthermore, we must be careful not to extend the findings of one LAA occlusion method to another.
We agree with Sarris-Michopoulos et al. that this is an exciting field that needs further randomized trials. The technology behind nonsurgical LAA occlusion techniques such as Watchman, Amplatzer Amulet, and Lariat will likely continue to evolve. There is good reason to hope that new iterations of these devices will have less complication rates but whether they can become the primary approach to prevent ischemic strokes is unknown. For example, the Watchman FLX device has an improved design to increase safety and efficacy.

We look forward to the results of the CHAMPION-AF study that will randomize patients to Watchman FLX versus DOAC treatment. Similar efforts are needed to provide evidence from randomized controlled trials for surgical techniques such as LAA clipping. While the therapeutic landscape is being investigated, it is also important to point out that there is tremendous opportunity to refine our diagnostic approach to stroke prevention in patients with AF. The current standard assessment – the CHA2DS2-VASc score – has only a mediocre C-statistic estimated to range from 0.61-0.68. The cumulative one year risk for thromboembolic events in patients with atrial fibrillation with CHA2DS2-VASc scores [?] 2 (accounting for 89% of the AF patients) who are not anticoagulated is estimated at 4.5%. This indicates that the majority of patients with atrial fibrillation do not experience stroke but are subjected to the risks of anticoagulation.

Better diagnostic approaches to identify which patients are at risk and which are not could have tremendous public health ramifications. There is active current interest in defining the atrial myopathy or cardiopathy that is associated with stroke. Several techniques have been under investigation, including LAA size/morphology, electrocardiogram P wave morphology, echocardiographic LA strain, epicardial adipose tissue, troponin and N terminal pro-brain natriuretic peptide levels, and 4D flow MRI to evaluate left atrial and LAA stasis. There is also ongoing research into “pill-in-pocket” anticoagulation that would use continuous smartwatch monitoring to target anticoagulation to intermediate risk patients during high risk time periods. Combined efforts in the diagnostic and therapeutic realm are most likely to achieve improved clinical results for stroke prevention in atrial fibrillation.

References


